SCHEMBL13051332

SCHEMBL13051332

Cc1cccc(/N=C/c2cccc(O)c2O)c1-c1c(C)cccc1/N=C/c1cccc(O)c1O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.79
▸ POLB P06746 7/20 0.79
▸ ALDH1A1 P00352 7/20 0.79
▸ KDM4E B2RXH2 7/20 0.79
▸ L3MBTL1 Q9Y468 5/20 0.79
▸ MPI P34949 3/20 0.79
▸ RECQL P46063 2/20 0.79
▸ GAA P10253 7/20 0.64
▸ HPGD P15428 5/20 0.64
▸ HSD17B10 Q99714 4/20 0.64
▸ ALOX15 P16050 4/20 0.64
▸ ALOX12 P18054 3/20 0.64
▸ LMNA P02545 3/20 0.64
▸ THRB P10828 3/20 0.64
▸ PKM P14618 2/20 0.64
▸ DHODH Q02127 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ AKR1C3 P42330 1/20 0.58
▸ AKR1C2 P52895 1/20 0.58
▸ AKR1C1 Q04828 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11877168 0.89 CA12 (0.68) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL11877164 0.89 CA12 (0.68) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL30355323 0.83 POLB (0.77) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL30355322 0.83 POLB (0.77) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL19974998 0.82 ALDH1A1 (0.77) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL19975001 0.82 ALDH1A1 (0.77) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL11409354 0.81 POLB (0.75) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL11409357 0.81 POLB (0.75) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL29358114 0.81 POLB (0.75) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL30139902 0.80 ALDH1A1 (0.73) MAPTPOLBALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298559-A1 OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-11-25 — — US disclosed
US-20100298559-A1 OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-11-25 — — US disclosed
EP-2233468-A1 OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST Nissan Chemical Industries, Ltd. (JP) 2010-09-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298559-A1 OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST C5, C9, CCNE1 MAPT 3244/4885POLB 890/4885ALDH1A1 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback